X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT LTD. AJANTA PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 28.3 -18.2 - View Chart
P/BV x 11.7 3.0 391.5% View Chart
Dividend Yield % 0.5 1.1 46.5%  

Financials

 AJANTA PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
WOCKHARDT LTD.
Mar-17
AJANTA PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,7201,129 152.3%   
Low Rs1,103627 175.9%   
Sales per share (Unadj.) Rs194.6363.1 53.6%  
Earnings per share (Unadj.) Rs45.2-20.4 -221.2%  
Cash flow per share (Unadj.) Rs50.3-7.0 -721.1%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.1 49.8%  
Book value per share (Unadj.) Rs132.0301.8 43.7%  
Shares outstanding (eoy) m88.77110.55 80.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x7.32.4 300.0%   
Avg P/E ratio x31.2-42.9 -72.7%  
P/CF ratio (eoy) x28.1-125.9 -22.3%  
Price / Book Value ratio x10.72.9 367.5%  
Dividend payout %17.7-48.9 -36.2%   
Avg Mkt Cap Rs m125,29997,063 129.1%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,5709,665 26.6%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m17,27540,146 43.0%  
Other income Rs m1661,143 14.6%   
Total revenues Rs m17,44241,289 42.2%   
Gross profit Rs m5,807128 4,536.9%  
Depreciation Rs m4511,489 30.3%   
Interest Rs m492,253 2.2%   
Profit before tax Rs m5,474-2,472 -221.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460-211 -691.6%   
Profit after tax Rs m4,014-2,260 -177.6%  
Gross profit margin %33.60.3 10,543.3%  
Effective tax rate %26.78.5 312.2%   
Net profit margin %23.2-5.6 -412.7%  
BALANCE SHEET DATA
Current assets Rs m7,63946,160 16.5%   
Current liabilities Rs m2,71519,258 14.1%   
Net working cap to sales %28.567.0 42.5%  
Current ratio x2.82.4 117.4%  
Inventory Days Days43101 42.9%  
Debtors Days Days7994 83.6%  
Net fixed assets Rs m6,91440,165 17.2%   
Share capital Rs m177553 32.0%   
"Free" reserves Rs m11,44232,814 34.9%   
Net worth Rs m11,72133,367 35.1%   
Long term debt Rs m14931,903 0.5%   
Total assets Rs m14,81489,687 16.5%  
Interest coverage x112.9-0.1 -116,282.5%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x1.20.4 260.5%   
Return on assets %27.40 -319,450.8%  
Return on equity %34.2-6.8 -505.6%  
Return on capital %46.5-0.3 -13,880.6%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,4229,121 114.3%   
Fx outflow Rs m1,6782,133 78.7%   
Net fx Rs m8,7446,988 125.1%   
CASH FLOW
From Operations Rs m3,264-2,695 -121.1%  
From Investments Rs m-2,093-6,863 30.5%  
From Financial Activity Rs m-1,18612,545 -9.5%  
Net Cashflow Rs m-153,010 -0.5%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS